Radiolabeled peptides for tumor imaging with positron emission tomography (PET) that can be produced with kits are currently in the spot light of radiopharmacy as well as nuclear medicine. The diagnosis of neuroendocrine tumors in particular has been a prime example for the usefulness of peptides labeled with a variety of different radionuclides. Among those, 68Ga and 18F stand out because of the ease of radionuclide introduction (e.g. 68Ga isotope) or optimal nuclide properties for PET imaging (slightly favoring 18F isotope). In vivo properties of GMP-compliant, newly developed kit-like producible 18F-SiFA- and 18F-SiFAlin- (SiFA = silicon-fluoride acceptor) modified TATE derivatives were compared to the current clinical gold standard 68Ga-DOTATATE for high quality imaging of somatostatin receptor-bearing tumors.

 

(후략)